15 research outputs found
Recommended from our members
The Oncogenic Regulation of Histone Lysine Lactylation
L-lactate is generated during glycolysis, a metabolic pathway that is widely associated with many physiological and disease related processes. We recently reported the discovery of lysine L-lactylation [K(L-la)] as a novel protein posttranslational modification occurring on histone proteins that can contribute to gene transcription. K(L-la) can be stimulated by L-lactate during macrophage polarization and a few types of differentiated culture cells. Excess L-lactate generation is a defining feature of cancer. However, it remains unknown if the elevated L-lactate in cancer cells will modulated histone K(L-la) that in turn regulate gene expression. Here, we report that the oncogenic signaling arising from the RAS-RAF-MAPK pathway can elevate histone K(L-la) levels through increased L-lactate synthesis stemming from the Warburg effect. Interestingly, the elevation of histone K(L-la) is correlated with intracellular lactate concentration in diverse types of cultured cancer cells. Inhibitors of key glycolysis enzymes regulates cellular lactate levels that in turn modulate histone K(L-la). Using quantitative proteomics, we demonstrate that distinct members of the MAPK pathway can differentially contribute to the abundance of specific histone K(L-la) sites. Lastly, we identify and validate MOF as a novel lactyltransferase both in vitro and in cells. Our study thus reveals that lysine L-lactylation is a histone mark that is dynamically regulated by oncogenic signals and MOF
Voltage-Gated Ion Channels in Cancer Cell Proliferation
Changes of the electrical charges across the surface cell membrane are absolutely necessary to maintain cellular homeostasis in physiological as well as in pathological conditions. The opening of ion channels alter the charge distribution across the surface membrane as they allow the diffusion of ions such as K+, Ca++, Cl−, Na+. Traditionally, voltage-gated ion channels (VGIC) are known to play fundamental roles in controlling rapid bioelectrical signaling including action potential and/or contraction. However, several investigations have revealed that these classes of proteins can also contribute significantly to cell mitotic biochemical signaling, cell cycle progression, as well as cell volume regulation. All these functions are critically important for cancer cell proliferation. Interestingly, a variety of distinct VGICs are expressed in different cancer cell types, including metastasis but not in the tissues from which these tumors were generated. Given the increasing evidence suggesting that VGIC play a major role in cancer cell biology, in this review we discuss the role of distinct VGIC in cancer cell proliferation and possible therapeutic potential of VIGC pharmacological manipulation
LIN-9 Phosphorylation on Threonine-96 Is Required for Transcriptional Activation of LIN-9 Target Genes and Promotes Cell Cycle Progression
<div><p>Cell cycle transitions are governed by the timely expression of cyclins, the activating subunits of Cyclin-dependent kinases (Cdks), which are responsible for the inactivation of the pocket proteins. Overexpression of cyclins promotes cell proliferation and cancer. Therefore, it is important to understand the mechanisms by which cyclins regulate the expression of cell cycle promoting genes including subsequent cyclins. LIN-9 and the pocket proteins p107 and p130 are members of the DREAM complex that in G0 represses cell cycle genes. Interestingly, little is know about the regulation and function of LIN-9 after phosphorylation of p107,p130 by Cyclin D/Cdk4 disassembles the DREAM complex in early G1. In this report, we demonstrate that cyclin E1/Cdk3 phosphorylates LIN-9 on Thr-96. Mutating Thr-96 to alanine inhibits activation of cyclins A2 and B1 promoters, whereas a phosphomimetic Asp mutant strongly activates their promoters and triggers accelerated entry into G2/M phase in 293T cells. Taken together, our data suggest a novel role for cyclin E1 beyond G1/S and into S/G2 phase, most likely by inducing the expression of subsequent cyclins A2 and B1 through LIN-9.</p></div
Phosphorylation of Thr-96 in LIN-9 is essential for transcriptional activation of cell cycle genes.
<p>(A) Indicated GFP-LIN-9 constructs were cotransfected into 293T cells, together with luciferase under the control of the promoters of cdc6, cyclin B1 or cyclin A2. Cell lysates were subjected to reporter gene assays using Promega Glo (Promega). Experiment was performed in triplicates. For the cdc6 promoter: n = 4, for the cyclin A and cyclin B promoters: n = 2; *p<0.05, **p<0.005, ***p<0.0005 (B) One of the three samples used in A was subjected to Western blot, using GFP antibody to detect expression of GFP-LIN-9 constructs. GFP-LIN-9<sup>T96D</sup> migrates faster and is always expressed at lower levels than GST-LIN-9 wild type and T96A.</p
cyclin E is essential for phosphorylation of Thr-96 in LIN-9 in vivo in primary cells.
<p>(A) p-LIN-9<sup>Thr-96</sup> antibody is specific. 293T cells were cotransfected with plasmids encoding GFP-LIN-9, FLAG-Cdk3 and cyclin E, and cell extracts were subjected to immunoprecipitation using a monoclonal LIN-9 antibody. IP material was split into two, and incubated for 1 hour at 30°C with or without lambda phosphatase. Samples were subjected to Western Blot using our p-LIN-9<sup>Thr-96</sup> antibody (upper panel). Equal loading of LIN-9 was confirmed by incubating the same membrane with a rabbit antibody against LIN-9 (lower panel). (B) HUVECs were transfected with siRNA control or siRNA directed against Cyclin E1 (Santa Cruz) using Dharmafect 4 (Dharmacon) and harvested after 48 hours. Western Blots was performed with the indicated antibodies. (C) T98G cells were starved in serum-free medium for 36 hours followed by the addition of growth medium (supplemented with 10% serum). Cells were harvested by tripsynization at the indicated time after the addition of serum and use for Western blot or FACS analysis. Western blots were performed as described in Methods.</p
LIN-9 is phosphorylated by and is found in a trimeric complex with Cdk3/cyclin E1.
<p>(A) GST-LIN-9 expressed in bacteria was subjected to in vitro kinase assays using indicated kinase complexes purchased from ProQinase. Asterisk indicates GST-cyclin autophosphorylation. The lower panel shows Coomassie blue staining of the same gel. (B) GST-LIN-9 was subjected to in vitro kinase assays using Flag-Cdk3 kinase complexes (Flag-IP) from human 293Tcells. Autoradiography visualizes incorporation of phospholabel and asterisks (white, placed to the left of the corresponding band) indicate autophosphorylation of cyclin E1 and cyclin A2, respectively (upper panel). Coomassie Brillant Blue (CBB) staining depicts loading of GST-LIN-9 and Flag-Cdk3 (second panel). Ten percent of IP material was subjected to Western blot to visualize amounts of co-precipitated cyclin A2 (third panel), cyclin E1 (fourth panel) and Flag-Cdk3 (lower panel). (C) 293T cells were cotransfected with Flag-Cdk3 and GFP-LIN-9, followed by Flag-IP. IP material was subjected to Western blots using LIN-9 antibody (upper panel), cyclin E1 antibody (middle panel) and Flag-antibody (lower panel).</p
Phosphorylation of Thr-96 in LIN-9 accelerates entry into G2/M.
<p>293T cells were transfected with the indicated LIN-9 constructs or GFP control and 24 hours later synchronized by serum starvation. Cells were released into the cell cycle by the addition of complete growth medium and harvested at 0, 6 and 12 hours for FACS analysis.</p
MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells
Quantification of BSA cross-linked peptide pairs with Skyline.
<p><b>A.</b> MS2 spectrum for the cross-linked peptide pair linking residues K235-K28 (ALK<sup>235</sup>AWSVAR_DTHK<sup>28</sup>SEIAHR), obtained from a 500 ng injection of cross-linked BSA digest. <b>B.</b> Extracted ion chromatograms for the PRM transitions observed for the cross-linked peptide pair in A. <b>C.</b> Skyline generated bar plot illustrating the normalized peak areas for the cross-linked peptide pair linking K28-K235. Peak areas are shown for triplicate analyses of varying injection amounts (100, 200, 500, and 1000 ng cross-linked BSA digest). Bars are color coded to indicate the contribution of each individual transition to the total peak area and match the color scheme in panel B. </p